Odds Ratio (95% Crl) Study **I**^2 **Chemotherapy vs Afatinib** 57  $\rightarrow$  1.1e+08 (8.3e-05, 1.4e+20)  $\rightarrow$  5.3e+19 (2.0, 2.3e+59) Pooled (pair-wise) 1.9 (0.033, 1.2e+02) Indirect (back-calculated) Pooled (network)  $\Rightarrow$  2.3 (0.056, 1.9e+02) 35.4% **Erlotinib** vs Afatinib 38 1.4 (0.28, 6.9)  $\rightarrow$  1.4 (6.0e-05, 3.2e+04) Pooled (pair-wise) Indirect (back-calculated) 2.5 (0.14, 45.) Pooled (network) 0.0%  $\rightarrow$  2.3 (0.20, 51.) Placebo vs Afatinib 54 0.32 (0.021, 4.8) Pooled (pair-wise)  $\rightarrow$  0.36 (9.9e–06, 7.2e+03) Indirect (back-calculated) 0.67 (0.032, 14.) Pooled (network) 0.0% 0.64 (0.028, 9.6) Gefitinib vs Almonertinib 4  $\rightarrow$  4.9e+07 (6.2e-05, 3.9e+19) Pooled (pair-wise) €2.6e+31 (13., 1.8e+124) NA Indirect (back-calculated) Pooled (network)  $\rightarrow$  3.7e+06 (0.58, 2.8e+21) Lazertinib vs Amivantamab Lazertinib  $\rightarrow$  0.71 (0.0036, 1.4e+02) **r**1  $\rightarrow$  0.80 (1.5e-05, 3.9e+04) Pooled (pair-wise) NA Indirect (back-calculated) Pooled (network) 1.7 (0.035, 92.) 0.1 10









